Fact-checked by Grok 2 weeks ago

Merthiolate

Merthiolate, the trade name for thimerosal (also known as thiomersal), is an organomercurial compound with the chemical formula C₉H₉HgNaO₂S, comprising approximately 49% mercury by weight and functioning as an ethylmercury derivative of thiosalicylic acid.^[1] Introduced in 1927 by Eli Lilly and Company, it served primarily as a topical antiseptic for minor wounds and skin infections, leveraging its broad-spectrum antibacterial and antifungal properties, and later as a preservative in multi-dose vaccines, immunoglobulin preparations, ophthalmic solutions, and other biologics to prevent microbial contamination.^[2]^[3] Its efficacy stemmed from the antimicrobial action of released ethylmercury ions, which disrupted microbial cell processes without the higher toxicity profile of inorganic mercury forms at low concentrations.^[4] Widespread adoption followed post-World War I advancements in antiseptics, with Merthiolate solutions becoming household staples for first aid until alternatives like alcohol-based antiseptics gained prominence.^[3] In vaccines, trace amounts (typically 25–50 micrograms per dose) extended shelf life in developing regions, though precautionary measures in the late 1990s—driven by theoretical risks of ethylmercury bioaccumulation akin to methylmercury—led to its removal from most single-dose U.S. childhood immunizations by 2001, while retaining use in some adult and global multi-dose vials.^[5] Safety assessments, including risk evaluations by regulatory bodies, have consistently identified no evidence of systemic harm from preservative-level exposures beyond transient local reactions like redness or swelling, with ethylmercury's faster elimination compared to methylmercury mitigating neurotoxicity concerns.^[6]^[5] Large-scale epidemiological studies across populations, involving millions of children, refuted hypothesized links to autism spectrum disorders or broader neurodevelopmental delays, attributing perceived associations to temporal correlations rather than causation.^[6] Nonetheless, isolated reports of hypersensitivity and debates over cumulative low-dose effects persist, particularly in contexts of iatrogenic overexposure, underscoring ongoing scrutiny of mercury-based compounds despite empirical data affirming low-risk profiles in standard applications.^[7]^[2]

Composition and Properties

Chemical Structure and Formulation

Thimerosal, the primary active compound in Merthiolate formulations, is systematically named sodium ethylmercurithiosalicylate and has the molecular formula C₉H₉HgNaO₂S.^[1] This organomercurial structure consists of an ethylmercury cation (C₂H₅Hg⁺) coordinated linearly to the sulfur atom of a deprotonated thiosalicylic acid (2-mercaptobenzoic acid) anion, with sodium as the counterion, conferring water solubility via the carboxylate group.^[1] The compound contains approximately 49.55% mercury by weight, calculated from its elemental composition.^[8] Thimerosal is synthesized through the reaction of ethylmercury chloride with thiosalicylic acid in the presence of aqueous sodium hydroxide, yielding the sodium salt after neutralization and purification steps.^[9] The resulting product is a white to cream-colored, odorless crystalline powder with a molecular weight of 404.81 g/mol.^[1] In terms of physical properties, thimerosal exhibits high solubility in water (approximately 1 g per 1 mL) and moderate solubility in alcohol (approximately 1 g per 8 mL), while being nearly insoluble in ether and benzene.^[10] It remains chemically stable under standard ambient conditions but may discolor upon prolonged exposure to light due to oxidative degradation.^[11] Commercial antiseptic formulations typically incorporate thimerosal at concentrations ranging from 0.001% to 0.01% to achieve antimicrobial activity while maintaining solution stability.^[5]

Mercury Content and Differentiation from Other Forms

Thimerosal, the organomercurial compound central to Merthiolate formulations, consists of approximately 49-50% mercury by weight, with the mercury atom integrated into an ethylmercury moiety linked to a thiosalicylate group via a mercurial bond.^[5] This ethylmercury structure distinguishes it from inorganic mercury salts, which lack the organic alkyl chain, and from methylmercury, an analogous organomercury form prevalent in environmental sources like contaminated fish.^[5] The ethylmercury in thimerosal undergoes enzymatic cleavage primarily in red blood cells, yielding inorganic mercury species that do not reform stable alkyl bonds, facilitating distinct metabolic handling.^[4] Pharmacokinetic profiles reveal ethylmercury's blood half-life in humans ranging from 3 to 7 days following exposure, driven by rapid conversion to inorganic mercury and subsequent biliary excretion into feces as the dominant clearance pathway.^[4] ^[12] In comparison, methylmercury exhibits a prolonged blood half-life of approximately 40-50 days, attributed to slower demethylation and greater affinity for sulfhydryl groups in proteins, promoting tissue retention.^[13] Human infant studies post-thimerosal administration confirm ethylmercury's elimination without detectable bioaccumulation, with peak blood levels declining exponentially within days and minimal urinary contribution to overall excretion.^[14] These biochemical differences underscore ethylmercury's transient presence in systemic circulation versus methylmercury's persistence, as evidenced by primate models where ethylmercury-derived mercury clears brain tissue more swiftly than methylmercury equivalents.^[12] Unlike inorganic mercury, which may accumulate in kidneys after prolonged exposure to soluble salts, ethylmercury's organic linkage enables faster gastrointestinal transit and fecal output post-metabolism, avoiding the renal tropism seen in direct inorganic dosing.^[15] Such distinctions arise from the ethyl group's lability under physiological conditions, contrasting with methylmercury's stability and lipophilicity.^[16]

Historical Development

Invention and Early Commercialization

Merthiolate, the proprietary brand name for thimerosal (sodium ethylmercurithiosalicylate), an organomercurial compound designed for bacteriostatic applications, originated from research conducted by chemist Morris Selig Kharasch. Working as an Eli Lilly and Company fellow at the University of Maryland, Kharasch synthesized the compound in 1927 to overcome the instability of prior mercury-based antiseptics, aiming for a formulation that combined ethylmercury with thiosalicylic acid for enhanced stability and antimicrobial action.^[1]^[3] Kharasch filed a patent application for thimerosal (U.S. Patent 1,672,615) in 1927, which was granted in 1928 and assigned to Eli Lilly, recognizing its potential as a non-irritating preservative and disinfectant. Initial laboratory evaluations demonstrated its efficacy in inhibiting bacterial growth, particularly against Gram-positive pathogens like Staphylococcus aureus, through disruption of microbial enzyme systems, prompting early tests for sterilizing surgical instruments, bandages, and biological specimens.^[17]^[7] Eli Lilly initiated commercialization by registering the Merthiolate trademark on January 29, 1929, for a 0.1% aqueous-alcoholic solution marketed as a topical antiseptic. The product entered the market in 1930, with over-the-counter availability supported by in vitro data showing superior preservation of solutions against contamination compared to alternatives like phenol, though formal FDA oversight at the time emphasized manufacturer-submitted efficacy claims rather than rigorous clinical trials.^[18]^[19]

Widespread Adoption in Medicine and Industry

Merthiolate, commercialized by Eli Lilly in 1927, achieved broad integration into topical medical formulations during the 1930s and 1940s, appearing in antiseptic solutions, ointments, eye washes, and nasal sprays for household first aid and clinical treatment of minor cuts, scrapes, and irritations.^[20]^[2] This expansion occurred amid limited antibiotic availability, where its antimicrobial action against bacteria such as hemolytic streptococci demonstrated utility in controlling wound infections through direct application, outperforming some contemporaries in preventing bacterial proliferation without requiring surgical intervention in tested models.^[21] By the 1940s, adoption extended to industrial-scale preservation of biological therapeutics, including immune sera, antitoxins, and vaccines stored in multi-dose vials, where it inhibited microbial growth and toxin activity during manufacturing and distribution—essential for wartime vaccine efforts when heat sterilization risked denaturing sensitive proteins.^[5]^[22] Its chemical stability allowed cost-effective maintenance of sterility in large-volume production, reducing contamination risks in pre-antibiotic biologicals and supporting empirical reductions in post-production spoilage.^[20] Through the 1950s, Merthiolate's role solidified in both medical and limited industrial contexts, such as cosmetics preservation, sustaining its position as a versatile agent for infection prevention until antibiotic alternatives matured.^[2]^[23]

Applications and Efficacy

Topical Antiseptic Uses

Merthiolate, typically formulated as a 0.1% aqueous solution of thimerosal, was applied topically to minor cuts, scrapes, and burns to disinfect the skin and prevent bacterial invasion.^[24]^[2] This concentration allowed for direct application without significant tissue irritation, targeting surface pathogens while promoting localized healing in first-aid scenarios.^[20] In vitro studies confirmed thimerosal's broad-spectrum antimicrobial efficacy, with minimum inhibitory concentrations effective against Gram-positive bacteria such as Staphylococcus aureus, Gram-negative species including Pseudomonas aeruginosa, and fungi like Candida albicans.^[25] Additional assays demonstrated superior inhibition of ocular pathogenic fungi compared to agents like amphotericin B and natamycin, underscoring its fungicidal potential in topical contexts.^[26] These properties stemmed from thimerosal's mercurial disruption of microbial enzyme systems, achieving rapid bactericidal and fungistatic effects at low dilutions.^[2] During the mid-20th century, particularly in the 1940s, Merthiolate saw routine use in preoperative skin preparation and postoperative wound care, where it was credited with contributing to declining sepsis rates amid improved aseptic techniques.^[20] Clinical observations from that era noted its role in suppressing hemolytic streptococci proliferation in infected tissues, supporting its adoption over earlier antiseptics like iodine tinctures.^[21] Over-the-counter availability of Merthiolate in the United States ended in 1998 following FDA reclassification, as non-mercurial alternatives such as benzalkonium chloride exhibited equivalent bacteriostatic performance against common wound pathogens without introducing heavy metal residues.^[23]^[27] This shift reflected broader regulatory prioritization of mercury-free formulations, with povidone-iodine also serving as a viable substitute for minor dermal antisepsis.^[28]

Role as a Biological Preservative

Thimerosal functions as a preservative in multi-dose vials of vaccines and other injectables by disrupting microbial metabolism and inhibiting the growth of bacteria and fungi, thereby preventing contamination during multiple punctures of the vial septum in clinical settings.^[5]^[29] This bacteriostatic and fungistatic action stems from the release of ethylmercury ions, which bind to sulfhydryl groups in microbial enzymes, averting overgrowth that could render the product unsafe or ineffective.^[30] Concentrations are standardized at levels providing 25–50 micrograms of mercury (equivalent to 50–100 micrograms of thimerosal, given its approximately 49% mercury content by weight) per 0.5 mL dose, sufficient to maintain sterility without compromising immunogenicity.^[5]^[31] In mass immunization campaigns, particularly in developing countries, thimerosal enables the use of multi-dose formats that reduce per-dose costs by up to 75% compared to single-dose vials and minimize demands on cold-chain infrastructure, facilitating broader access in areas with limited refrigeration and transportation.^[32]^[33] The World Health Organization endorses its retention in such contexts, citing empirical prevention of contamination-related morbidity, including historical outbreaks like those in the 1980s where preservative-free multi-dose vaccines led to bacterial infections and deaths in pediatric programs.^[29]^[34] Post-1999 precautionary efforts in high-income nations phased thimerosal out of routine childhood vaccines, achieving near-elimination in single-dose presentations by 2001 to minimize ethylmercury exposure, though multi-dose influenza vaccines (e.g., certain seasonal formulations) and tetanus toxoid products continue to incorporate it for logistical viability in global supply chains.^[35]^[5] This selective retention underscores its causal efficacy in stabilizing vaccine stocks against microbial proliferation, outweighing alternatives in scenarios prioritizing volume and shelf-life over mercury avoidance.^[30]^[31]

Comparative Effectiveness Against Pathogens

Thimerosal, at concentrations of 100 µg/ml, achieves complete growth inhibition of Pseudomonas aeruginosa in vitro, demonstrating bacteriostatic efficacy against this common contaminant in biological formulations.^[36] This minimum inhibitory concentration (MIC) aligns with standard preservative levels (0.01% w/v), where thimerosal prevents microbial proliferation in multi-dose vials by disrupting sulfhydryl groups in bacterial enzymes.^[5] Limited data exist for Clostridium species, but thimerosal's activity is primarily against vegetative cells, with reduced potency against anaerobes compared to quaternary ammonium compounds like benzalkonium chloride, which exhibit lower MICs (e.g., 1-10 µg/ml) for some Gram-positive clostridia.^[37] In comparative evaluations of preservatives for ophthalmic products containing chloramphenicol, thimerosal at 0.001% maintained sterility, pH stability, and antibacterial potency equivalent to benzalkonium chloride (0.01%) and benzyl alcohol (0.9%), with no microbial growth detected after challenge tests over 28 days.^[38] However, in pneumococcal conjugate vaccine formulations like Prevnar 13, 2-phenoxyethanol demonstrated superior antimicrobial effectiveness over thimerosal, reducing microbial recovery to undetectable levels faster under simulated use conditions.^[39] Thimerosal often shows synergistic effects when combined with alcohols or phenols, enhancing overall preservation in biologics by broadening spectrum coverage and extending shelf life beyond 2 years without refrigeration in resource-limited settings, where alternatives like phenol fail due to narrower activity.^[30] A key limitation is thimerosal's ineffectiveness against bacterial spores, such as those of Clostridium difficile, necessitating autoclaving or filtration for sterilization in spore-prone environments; organomercurials lack the oxidative or hydrolytic mechanisms required for sporicidal action, unlike glutaraldehyde or peracetic acid.^[40] This confines its role to adjunctive preservation rather than standalone sterilization in high-risk biologics.^[41]

Safety Profile and Toxicological Data

Mechanisms of Mercury Absorption and Clearance

Ethylmercury, the active mercurial component in thimerosal (Merthiolate), exhibits route-dependent absorption kinetics. Dermal penetration from topical applications occurs at rates up to approximately 10%, influenced by skin integrity, formulation, and exposure duration, resulting in limited but measurable systemic uptake.^[42] In contrast, parenteral routes such as intramuscular injection achieve near-complete bioavailability, with rapid distribution into blood and tissues following administration.^[14] Once absorbed, ethylmercury attains peak blood concentrations within hours to days, depending on dose and route, before undergoing biphasic elimination. Human pharmacokinetic data from thimerosal-containing vaccines indicate blood half-lives of 2.0 to 3.7 days in infants, with initial rapid clearance followed by slower terminal phases.^[43] Animal models corroborate this, showing blood mercury declining 5.4-fold faster post-thimerosal exposure compared to methylmercury equivalents.^[12] Hepatically, ethylmercury is primarily metabolized via cleavage of the ethyl group, yielding inorganic mercury through enzymatic dealkylation processes in the liver and kidneys; this conversion occurs more rapidly than for methylmercury, reducing lipophilicity and tissue retention.^[34] The resultant inorganic species binds to thiols and is secreted into bile, facilitating fecal excretion as the dominant clearance pathway—accounting for over 90% of elimination in tracer studies—while urinary output remains minor.^[4] At preservative concentrations (typically yielding <25 μg mercury per dose), ethylmercury does not bioaccumulate, as clearance rates exceed input, maintaining subthreshold blood levels without progressive buildup, unlike sustained low-level environmental exposures to more persistent mercury forms.^[43]^[12] This dose-dependent pharmacokinetics underscores thresholds below which steady-state accumulation is negligible, supported by compartmental modeling from repeated low-dose administrations.^[4]

Empirical Evidence on Acute and Chronic Exposure Risks

Acute exposure to thimerosal, primarily through topical application, is associated with rare hypersensitivity reactions, most commonly delayed-type contact dermatitis. In patch testing of patients referred to specialized dermatology units, positive reactions occurred in approximately 1% of individuals screened for contact allergens.^[44] Similarly, among 2461 adults evaluated for suspected contact allergy between 1987 and 1992, 1.3% exhibited positive patch tests to 0.1% thimerosal in petrolatum.^[45] These reactions typically present as localized erythema, edema, or vesicular eruptions within 24-72 hours, resolving upon discontinuation without systemic involvement in the vast majority of cases. Chronic exposure risks from standard thimerosal doses in vaccines have not been substantiated in large cohort studies or meta-analyses involving millions of children. The Institute of Medicine's 2001 review of available toxicological data concluded that only delayed hypersensitivity, not systemic chronic effects, has been demonstrated at low ethylmercury doses equivalent to vaccine exposure.^[34] Post-vaccination blood mercury levels peak transiently but remain well below safety thresholds, with maximum observed concentrations of ≤8 ng/mL in infants shortly after immunization.^[43] Ethylmercury's half-life in blood averages 2.9-4.1 days, preventing accumulation even with cumulative doses up to 187.5 μg by 6 months of age in historical vaccine schedules.^[46] Isolated incidents of pediatric acrodynia, characterized by painful acral erythema, irritability, and pink papules, have been linked to excessive topical mercury exposure, though such cases predominantly involve inorganic or other organic forms rather than standard thimerosal applications.^[47] These underscore absorption risks from non-prescribed overuse, as mercury vapor or compound penetration through intact skin is minimal under normal antiseptic use, but systemic toxicity emerges only with prolonged, high-volume application exceeding recommended limits. No large-scale series confirm chronic thimerosal-specific acrodynia from therapeutic topical dosing.^[34]

Distinctions Between Ethylmercury and Methylmercury Toxicity

Ethylmercury, the metabolite of thimerosal (Merthiolate), exhibits a markedly shorter biological half-life in blood compared to methylmercury, typically ranging from 3 to 7 days in humans, with infant studies reporting values as low as 6.9 days, facilitating rapid excretion primarily via feces after conversion to inorganic mercury.^[6]^[12] In contrast, methylmercury's half-life extends to 40–70 days, promoting tissue accumulation, particularly in the brain and kidneys, due to its high lipid solubility and efficient gastrointestinal absorption.^[48]^[49] This pharmacokinetic disparity underlies ethylmercury's lower persistence in the body, reducing the risk of chronic buildup observed with methylmercury exposures from environmental sources like contaminated fish.^[16] Regarding neurotoxicity, methylmercury's greater lipid solubility enables superior penetration of the blood-brain barrier, leading to selective neuronal damage and bioaccumulation in gray matter, as evidenced by its causal role in Minamata disease outbreaks where industrial wastewater contamination resulted in widespread neurological impairments including ataxia, sensory loss, and cognitive deficits among affected populations in Japan starting in the 1950s.^[50] Ethylmercury, while capable of crossing the blood-brain barrier, demonstrates lower brain retention; animal models in infant monkeys exposed to thimerosal-derived ethylmercury showed brain mercury levels 10-fold lower than those from equivalent methylmercury doses, with rapid clearance and minimal conversion to persistent forms.^[12]^[51] In animal toxicology studies, ethylmercury induces dose-dependent effects such as oxidative stress and transient behavioral alterations in rodents and primates, which largely resolve upon exposure cessation due to its quick metabolism and elimination, unlike methylmercury's irreversible cumulative damage manifesting as persistent demyelination and neurodegeneration.^[52] For instance, equimolar comparisons in rats revealed ethylmercury to be less neurotoxic by measures of motor function and histopathology, though higher doses could approximate methylmercury's severity, highlighting the importance of exposure magnitude but affirming ethylmercury's more benign profile at preservative-relevant levels.^[51] Human biomarker analyses, including data from vaccine surveillance, confirm distinct exposure profiles: thimerosal-derived ethylmercury peaks transiently post-vaccination without overlapping the sustained elevations from dietary methylmercury, as urinary and blood mercury patterns in immunized infants diverge from those in fish-consuming cohorts.^[53]^[6] These empirical distinctions underscore that equating the two compounds overlooks causal differences in persistence and tissue targeting, with ethylmercury's risks tied to acute rather than bioaccumulative mechanisms.^[16]

Controversies and Scientific Debates

Claims Linking to Neurodevelopmental Disorders

In the late 1990s, parents of children diagnosed with autism spectrum disorders began reporting temporal associations between routine childhood vaccinations containing thimerosal and the onset of neurodevelopmental regressions, including speech delays, tics, and loss of acquired skills.^[54] These anecdotal accounts posited that ethylmercury from thimerosal mimicked symptoms of chronic mercury poisoning, such as irritability, motor dysfunction, and sensory processing issues, which overlapped with autism traits.^[55] Small-scale studies in the early 2000s amplified these observations. For instance, a 2001 ecological analysis suggested that thimerosal exposure correlated with rising autism rates, attributing this to ethylmercury accumulation exceeding safe thresholds in infants' immature detoxification systems.^[55] Subsequent analyses by Mark and David Geier, using Vaccine Adverse Event Reporting System (VAERS) data and cohort comparisons, claimed higher incidences of autism, speech disorders, and attention-deficit/hyperactivity disorder among children receiving thimerosal-containing diphtheria-tetanus-acellular pertussis vaccines compared to thimerosal-free alternatives.^[56] These studies argued that prenatal and postnatal ethylmercury doses—up to 187.5 micrograms by six months in the U.S. schedule—could precipitate neurotoxicity in genetically susceptible individuals, manifesting as tics, language impairments, and behavioral regressions. Proponents advanced mechanistic hypotheses centered on ethylmercury's chemical reactivity. As an organomercurial, thimerosal-derived ethylmercury exhibits high affinity for sulfhydryl (-SH) groups in thiols, potentially binding and depleting glutathione (GSH), the primary cellular antioxidant.^[57] This depletion, in turn, was hypothesized to trigger oxidative stress by impairing redox homeostasis, leading to lipid peroxidation, protein damage, and mitochondrial dysfunction in vulnerable fetal and infant brains.^[58] Researchers contended that infants with polymorphisms in GSH-related genes (e.g., GSTP1 or GSTM1) might experience amplified effects, as reduced sulfation capacity hinders ethylmercury clearance, exacerbating neuronal apoptosis and synaptic disruptions akin to those in mercury-induced acrodynia.^[57] Advocacy organizations, drawing on interpretations of raw data presented at the 2000 Simpsonwood CDC conference, further propagated these claims. Groups highlighted transcript excerpts suggesting preliminary signals of neurodevelopmental risks from thimerosal, arguing that ethylmercury burdens paralleled rising disorder prevalences despite the absence of clear dose-response patterns in the discussed datasets.^[59] These interpretations, often linked to broader vaccine skepticism influenced by figures like Andrew Wakefield, emphasized precautionary removal to avert potential harm in subpopulations, framing thimerosal as a plausible environmental trigger for disorders like autism through cumulative bioaccumulation.^[7]

Large-Scale Studies and Epidemiological Findings

A population-based ecological study in Denmark analyzed autism incidence rates among 467,450 children born from 1973 to 1996, leveraging the nationwide discontinuation of thimerosal in vaccines starting in 1992 as a natural experiment to test causality. Despite the complete removal of thimerosal exposure, autism diagnoses continued to increase at the same rate in cohorts with and without thimerosal-containing vaccines, yielding a relative risk of 0.85 (95% CI, 0.60-1.20) for autism in the exposed versus unexposed groups, with no evidence of a temporal association. This controlled comparison refutes a causal role for thimerosal, as a true causative agent would predict a decline in incidence post-removal. The 2004 Institute of Medicine (IOM) comprehensive review evaluated more than 10 epidemiological studies, including large cohort analyses from the United States, United Kingdom, and Denmark, alongside case-control designs, and rejected a causal link between thimerosal-containing vaccines and autism. Key among these was the Verstraeten analysis of the Vaccine Safety Datalink database covering over 140,000 children, where an initial relative risk signal of 1.8 for autism in preliminary phase I data (unadjusted for confounders) diminished to 1.0 after phase II adjustments for birth year, healthcare utilization, and other biases, confirming no consistent association across datasets. The IOM's synthesis emphasized that biological plausibility alone cannot override null findings from multiple, methodologically robust population studies.^[60] A 2023 systematic review and meta-analysis of 44 studies involving over 4,000 participants compared mercury levels in hair, urine, and whole blood between individuals with autism spectrum disorder (ASD) and neurotypical controls, finding no statistically significant differences (standardized mean difference for hair: -0.11, 95% CI -0.35 to 0.13; for urine: 0.05, 95% CI -0.18 to 0.28). These results align with pharmacokinetic data on ethylmercury from thimerosal, which exhibits rapid renal clearance with a half-life of 3-7 days and minimal tissue accumulation, in contrast to persistent methylmercury, thereby excluding chronic mercury burden as a mechanism for ASD.

Minority Viewpoints and Mechanistic Hypotheses

A minority hypothesis posits that symptoms of autism spectrum disorder (ASD) overlap significantly with those of mercury poisoning, including sensory sensitivities, motor impairments, and behavioral dysregulation, as articulated in a 2001 analysis by Bernard et al., which drew parallels based on clinical manifestations observed in acrodynia cases from historical ethylmercury exposures.^[61] This view is mechanistically grounded in thimerosal's ethylmercury component binding to sulfhydryl (thiol) groups in proteins, disrupting cellular enzymes and antioxidant systems in vitro, thereby impairing mercury detoxification pathways that rely on thiol-dependent metallothioneins and glutathione.^[55] Proponents argue that such disruptions could preferentially affect vulnerable neural tissues during early development, though this remains contested due to differences in exposure routes and durations compared to chronic inorganic mercury poisoning. Critics of large epidemiological studies dismissing thimerosal's risks contend that these analyses often overlook individual variability in mercury handling, particularly genetic polymorphisms in metallothionein genes (e.g., MT1A, MT2A) or glutathione-related pathways (e.g., GSTP1), which impair binding, sequestration, and excretion of mercury, leading to elevated intracellular burdens even at low doses.^[62] For instance, certain single-nucleotide polymorphisms reduce metallothionein expression or function, exacerbating oxidative stress and thiol depletion in genetically susceptible individuals, a factor not stratified in many cohort designs.^[63] This genetic susceptibility angle suggests that population-level null findings may mask subgroups with heightened sensitivity, akin to pharmacogenetic variations in drug metabolism. Emerging mechanistic investigations highlight thimerosal's induction of mitochondrial dysfunction as a potential subtle endpoint, with in vitro studies on neuronal cells showing concentration-dependent reductions in oxidative-reduction activity, cytochrome c release, and ATP production at micromolar levels, independent of overt cytotoxicity.^[64] Animal models corroborate dose-dependent behavioral alterations; neonatal thimerosal administration in rats (1.0 μg Hg/kg) yielded persistent dopamine system changes and neurobehavioral deficits, including reduced social interaction and locomotor hyperactivity, persisting into adulthood.^[65] Similarly, intermittent dosing in SJL/J mice (a strain prone to autoimmunity) produced delayed neural development and altered gait, underscoring strain-specific vulnerabilities that parallel human genetic heterogeneity.^[66] These findings, while from higher exposures than typical vaccine schedules, propose causal pathways via bioenergetic impairment that warrant further exploration in susceptible models.

Regulatory History and Restrictions

United States FDA and EPA Actions

In 1998, the FDA prohibited the over-the-counter (OTC) use of thimerosal in topical antimicrobial drug products, including antiseptics like Merthiolate, after determining it was not generally recognized as safe and effective due to risks of mercury absorption through the skin.^[67]^[19] On July 9, 1999, the American Academy of Pediatrics (AAP) and the U.S. Public Health Service (PHS), including input from the FDA and CDC, issued a joint statement recommending the removal or reduction of thimerosal from vaccines routinely recommended for infants under six months of age as a precautionary measure to minimize mercury exposure, despite acknowledging no evidence of harm from low-level thimerosal exposure.^[68]^[69] This prompted vaccine manufacturers to reformulate products, resulting in thimerosal-free or trace-level versions for most U.S. childhood vaccines by 2001.^[70] In 2000, the FDA reviewed thimerosal's role in vaccines, affirming its necessity as a preservative in multi-dose vials to prevent microbial contamination while supporting phase-out efforts where single-dose or alternative formulations were feasible, driven by the precautionary approach rather than demonstrated toxicity.^[5]^[71] The EPA, lacking specific exposure guidelines for ethylmercury, applied conservative methylmercury reference dose limits (0.1 μg/kg body weight per day) to thimerosal assessments, which highlighted theoretical exceedances in infant vaccine schedules and reinforced the 1999 precautionary push for reduction, later influencing FDA requirements for thimerosal labeling on preserved vaccines in the 2010s.^[5]^[71]

International Bans and Precautionary Measures

In the European Union, thiomersal (thimerosal) faced restrictions under Regulation (EC) No 1223/2009 on cosmetic products, which prohibited the use of mercury compounds including thiomersal effective December 1, 2010, as part of broader efforts to eliminate non-essential mercury exposure despite limited evidence of unique risks from low-dose preservative applications.^[72] For pediatric vaccines, the European Medicines Agency recommended phasing out thiomersal from routine childhood immunizations by 2007, prioritizing mercury-free alternatives under the precautionary principle, even as toxicological data indicated ethylmercury from thiomersal clears rapidly and lacks the bioaccumulation seen in environmental methylmercury.^[73] These measures reflected a policy emphasis on minimizing any potential mercury intake in developed markets, irrespective of empirical equivalence in safety profiles across preservative types. Contrasting this, the World Health Organization has maintained endorsement of thiomersal in multi-dose vaccine vials for low- and middle-income countries, arguing that its antimicrobial efficacy prevents bacterial contamination and resultant deaths from spoiled vaccines, with cost analyses showing single-dose alternatives could raise immunization expenses by 200% to over 500% per dose in resource-constrained settings.^[74] This stance underscores a utilitarian risk-benefit calculus, where the documented hazards of vaccine wastage and infection outbreaks—estimated to cause thousands of preventable fatalities annually in developing regions—outweigh hypothetical ethylmercury concerns unsupported by large-scale neurodevelopmental outcome data.^[75] Country-level actions further highlight precautionary divergences detached from causal evidence of harm. Denmark discontinued thiomersal in vaccines in 1992, yet national autism incidence rates rose from 0.4 to 1.0 per 1,000 children post-removal through 2000, providing ecological counter-evidence to toxin-autism hypotheses and illustrating bans driven by public apprehension rather than observed risk reductions.^[76] Similar early removals in Sweden around 1990 correlated with stable or increasing autism diagnoses, reinforcing that such policies in high-income nations often prioritize perceptual safety over uniform application of global toxicological empirics, while poorer countries retain usage to sustain vaccination coverage amid logistical constraints.^[77] This asymmetry critiques regulatory frameworks that vary by economic status, potentially amplifying inequities in vaccine access without commensurate gains in population health metrics.

Post-2000 Phase-Outs and Ongoing Use

Following the voluntary phase-out of thimerosal from most U.S. childhood vaccines by 2001, it persisted as a preservative in multi-dose vials of seasonal influenza vaccines, which are predominantly administered to adults to prevent microbial contamination during repeated access.^[6] This formulation allowed for cost-effective storage and distribution in resource-limited settings, where single-dose alternatives proved logistically challenging despite their availability.^[5] Veterinary applications similarly retained thimerosal in certain animal biologics, such as vaccines and immunoglobulins, to maintain product integrity against bacterial growth over extended shelf life.^[78] The 2009 H1N1 influenza pandemic underscored thimerosal's role in supply chain resilience, as multi-dose vials containing the preservative enabled rapid scaling of vaccine production and averted widespread shortages amid surging global demand.^[79] Without it, the reliance on single-dose formats would have constrained output, given manufacturing constraints and the need for preservatives in opened containers to inhibit contamination risks.^[80] Residual thimerosal traces, yielding less than 1 mcg of mercury per dose, appeared in some thimerosal-reduced single-dose vaccines due to unavoidable carryover in production lines, though levels remained below detectable thresholds for toxicity.^[5] Post-marketing surveillance via the Vaccine Adverse Event Reporting System (VAERS) documented no statistically significant elevation in report rates of serious adverse events linked to these exposures, consistent with ethylmercury's rapid clearance pharmacokinetics.^[81]

Recent Developments and Current Status

2020s Policy Shifts and ACIP Recommendations

In June 2025, the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) voted during its June 25-26 meeting to recommend against the use of thimerosal-containing influenza vaccines for all age groups, including children under 18, pregnant individuals, and adults, prioritizing single-dose, thimerosal-free formulations due to their widespread availability.^[82]^[83] The vote, which passed 5-1-1, reflected a precautionary approach amid ongoing public concerns, despite the absence of new empirical evidence demonstrating toxicity from ethylmercury in thimerosal at vaccine doses, as prior large-scale reviews had affirmed rapid clearance from the body and no causal links to adverse outcomes.^[84]^[85] On July 23, 2025, the U.S. Department of Health and Human Services (HHS), under Secretary Robert F. Kennedy Jr., adopted the ACIP's recommendation, directing the phase-out of thimerosal from all U.S. influenza vaccines for the 2025-2026 season to "restore trust" in vaccination programs.^[86] This policy shift occurred against a backdrop of stagnant safety data, with thimerosal already reduced or eliminated from most childhood vaccines since 2001, yet autism prevalence rates continuing to rise from 1 in 150 children in 2000 to 1 in 36 by 2020, uncorrelated with thimerosal exposure declines.^[87] Reporting from outlets like NPR highlighted public and advocacy pressures, including from figures skeptical of vaccine ingredients, as influencing the revamped ACIP's decision, rather than novel toxicological findings.^[87] Critics, including vaccine experts and organizations like the American Academy of Pediatrics, argued the move diverts attention from core issues like vaccine access in multi-dose vials for resource-limited settings, where thimerosal prevents bacterial contamination without demonstrated harm, potentially complicating global supply chains without causal benefits to public health.^[88]^[89] Ethylmercury's pharmacokinetics—faster renal excretion compared to methylmercury—underscore the empirical disconnect, as precautionary elimination overlooks decades of surveillance data showing no population-level neurodevelopmental risks tied to its use.^[82] This 2025 recommendation marks a continuation of 2020s trends toward ingredient avoidance driven by perception over updated evidence, with thimerosal's role now negligible in U.S. routine immunization.^[90]

Global Disparities in Usage and Access

In low- and middle-income countries, particularly in Africa and Asia, thimerosal-containing multi-dose vials (MDVs) remain the preferred format for vaccines such as tetanus toxoid, as endorsed by the World Health Organization (WHO) for large-scale immunization campaigns into the 2020s, enabling efficient delivery without widespread bacterial contamination that could otherwise lead to infections.^[46] These MDVs, preserved with thimerosal at concentrations of 0.01%, have demonstrated effectiveness in preventing microbial growth, with global surveillance data indicating contamination rates below 1% when proper handling protocols are followed, compared to higher risks in non-preserved formats that contribute to an estimated 1.7 million unsafe injections annually in developing regions.^[75] For instance, tetanus elimination initiatives in sub-Saharan Africa, targeting over 100 million women of childbearing age as of 2023, rely on thimerosal-stabilized MDVs to maintain vial integrity during field campaigns, averting outbreaks linked to contaminated single-use alternatives.^[91] Regulatory restrictions in high-income nations, which phased out thimerosal from most childhood vaccines by the early 2000s, have driven a shift to single-dose vials (SDVs), increasing production and logistics costs by 20-50% due to higher filling requirements, reduced economies of scale, and expanded cold-chain demands—disparities that amplify vaccine hesitancy and access barriers in resource-limited settings without corresponding reductions in neurodevelopmental risks.^[32] In contrast, continued MDV use in thimerosal-reliant regions correlates with lower infection rates from vial contamination, as evidenced by WHO-monitored programs where preserved MDVs yield adverse injection-site event rates under 0.5%, versus 2-5% in preservative-free multi-use scenarios prone to bacterial proliferation.^[92] This equity gap underscores how precautionary bans in wealthier countries elevate global vaccine pricing—SDVs costing up to three times more per dose—potentially delaying coverage in areas where thimerosal's preservative role directly mitigates sepsis and abscess risks from improper storage.^[93] Global adverse event surveillance through systems like the WHO's Vigibase and CDC's Vaccine Adverse Event Reporting System (VAERS) equivalents, covering over 1 billion doses administered in thimerosal-containing vaccines as of mid-2025, shows no detectable uptick in neurodevelopmental disorders or mercury-related toxicities attributable to ongoing use in MDV formats.^[6] Epidemiological analyses from 2020-2025, including cohort studies in Asia and Africa, confirm ethylmercury clearance within 30 days post-vaccination and absence of causal links to autism spectrum disorder, with incidence rates stable or declining amid expanded immunization amid infectious disease burdens.^[94] These findings highlight a regulatory asymmetry where thimerosal's removal in affluent settings yields no safety dividends but imposes cost burdens that hinder equitable access, perpetuating higher contamination-driven morbidity in preservative-dependent regions.^[89]

References

[1]
Thimerosal | C9H9HgNaO2S | CID 16684434 - PubChem - NIH
Thimerosal is an alkylmercury compound (approximately 49% mercury by weight) used as an antiseptic and antifungal agent. It has a role as a disinfectant, an ...
[2]
A review of Thimerosal (Merthiolate) and its ethylmercury ... - PubMed
Thimerosal (Merthiolate) is an ethylmercury-containing pharmaceutical compound that is 49.55% mercury and that was developed in 1927.Missing: composition | Show results with:composition
[3]
Thimerosal - American Chemical Society
Aug 9, 2011 · Thimerosal is a mercury-based topical antiseptic and antifungal agent that is sold under the trade name Merthiolate. It is also used as a vaccine preservative.
[4]
Thimerosal: Uses, Interactions, Mechanism of Action - DrugBank
Apr 29, 2016 · Thimerosal is an organomercurial compound and derivative of thiosalicyclic acid with antibacterial and antifungal properties. Thimerosal, which ...Missing: composition | Show results with:composition
[5]
Thimerosal and Vaccines - FDA
Jan 15, 2025 · Thimerosal, which is approximately 50% mercury by weight, has been one of the most widely used preservatives in vaccines.Missing: controversies | Show results with:controversies
[6]
Thimerosal and Vaccines - CDC
A risk assessment of thimerosal use in childhood vaccines finds no evidence of harm from the use of thimerosal as a preservative, other than redness and ...Missing: Merthiolate | Show results with:Merthiolate
[7]
Mercury, Vaccines, and Autism: One Controversy, Three Histories
The controversy regarding the once widely used mercury-containing preservative thimerosal in childhood vaccines has raised many historical questions that have ...
[8]
Thimerosal | CAS# 54-64-8 | ethylmercury-sulfidobenzoate | MedKoo
Name: Thimerosal. CAS#: 54-64-8. Chemical Formula: C9H9HgNaO2S. Exact Mass: 405.9927. Molecular Weight: 404.81. Elemental Analysis: C, 26.70; H, 2.24; Hg, 49.55 ...
[9]
Thiomersal - MOTM 2015 - JMol version
The standard method seems to be that employed by Kharasch, reaction between ethylmercury-chloride, aqueous sodium hydroxide and thiosalicylic acid.
[10]
https://www.sigmaaldrich.com/deepweb/assets/sigmaaldrich/product/documents/317/780/t5125pis.pdf
[11]
[PDF] Thimerosal - Santa Cruz Biotechnology
Soluble in water and alcohol. Almost insoluble in ether and benzene. Discolours on exposure to light. Section 10 - CHEMICAL STABILITY. CONDITIONS CONTRIBUTING ...
[12]
Thimerosal and Animal Brains: New Data for Assessing ... - NIH
In the thimerosal group, the half-life of total mercury in blood was 6.9 days, compared to 19.1 days for the methylmercury group. Brain concentrations of total ...
[13]
Thimerosal in Vaccines: Myths vs. Medical Facts
Jul 7, 2025 · First discovered and patented by Morris Kharasch in 1928, thimerosal was developed in an effort to expand its antimicrobial and antifungal ...
[14]
Toxicity of ethylmercury (and Thimerosal): a comparison with ...
Feb 11, 2013 · The blood half-lives after thimerosal were 2.1 and 8.6 days (corresponding to days 2 and 38 after injection), whereas that of meHg was 21.5 ...<|separator|>
[15]
A systematic study of the disposition and metabolism of mercury ...
Hg substantially accumulates in kidney with a terminal half-life of 45.2 d. •. The dealkylation of ethylmercury occurs in red blood cells but not in plasma. •.
[16]
Toxicity of ethylmercury (and Thimerosal): a comparison ... - PubMed
Feb 11, 2013 · Ethylmercury (etHg) has a shorter blood half-life than methylmercury (meHg) and different toxicity profiles, potentially leading to different ...
[17]
[PDF] MERCURY, A SINGULAR METAL
A patent (US1672615) (28) was applied for in 1927 by organic chemist Morris Selig Kharasch from College Park, Maryland Later, the pharmaceutical giant Eli ...<|separator|>
[18]
MERTHIOLATE - Eli Lilly And Company Trademark Registration
Timeline ; 1928-09-17, Application Filed ; 1929-01-29, Trademark Registered ; 1975-07-01, Published ; 1975-07-01, Republished 12(c) ; 1981-11-24, Cancelled.
[19]
Eli Lilly and Thimerosal - In These Times
Nov 11, 2003 · Eli Lilly and Co., the Indianapolis-based drug giant, developed and registered thimerosal under its trade name Merthiolate in 1929 and began marketing it as an ...Missing: history | Show results with:history
[20]
(PDF) A Review of Thimerosal (Merthiolate) and its Ethylmercury ...
Aug 7, 2025 · Thimerosal (Merthiolate) is an ethylmercury-containing pharmaceutical compound that is 49.55% mercury and that was developed in 1927.
[21]
antibacterial action of "merthiolate" against hemolytic streptococci
preventing infection following topical application required surgical procedures (Nungester, W. J. , and. Kempf, A. H. : An "Infection-Prevention" Test for.
[22]
Thimerosal and Vaccines — A Cautionary Tale
The use of mercury in vaccines wasn't new; thimerosal, an ethylmercury-containing preservative, had been used to prevent bacterial contamination since the 1930s ...
[23]
Mercury in OTC Medicine: Why Did the FDA Ban Mercurochrome ...
Jul 21, 2025 · Thimerosal was also used in nasal sprays, eye wash, diaper rash treatment and vaginal spermicides. Since virtually every household in America ...
[24]
Merthiolate: Indications, Side Effects, Warnings - Drugs.com
Nov 10, 2023 · Use Merthiolate (benzalkonium chloride) as ordered by your doctor. Read all information given to you. Follow all instructions closely.
[25]
In vitro assessment of Thimerosal cytotoxicity and antimicrobial activity
Thimerosal is a mercury compound, and there is a debate as to whether Thimerosal exposure from vaccination can contribute to the incidence of mercury-driven ...
[26]
In Vitro Activity of Thimerosal against Ocular Pathogenic Fungi - PMC
Thimerosal's antifungal activity was significantly superior to those of amphotericin B and natamycin against ocular pathogenic fungi in vitro.
[27]
Merthiolate Alternatives Compared - Drugs.com
Merthiolate Alternatives Compared ; Merthiolate (benzalkonium chloride) ; Betadine (povidone iodine) ; Sodium hypochlorite topical.Missing: discontinued 1998
[28]
What is a drug similar to merthiolate (thimerosal)? - Dr.Oracle AI
Jun 17, 2025 · Its use in wound care has been evaluated in various studies, demonstrating its safety and efficacy in promoting wound healing 3, 4. Additionally ...
[29]
Thiomersal - World Health Organization (WHO)
Its primary purpose has been to prevent microbial growth in the product during storage and use, as well as to inactivate certain organisms and toxins during ...
[30]
Why there is a role for thimerosal in vaccines - AAP Publications
Feb 1, 2015 · Thimerosal is a mercury-containing organic compound used for decades in the United States and other countries as a preservative in vaccines and other biologic ...
[31]
Thimerosal in Flu Vaccine | Influenza (Flu) - CDC
Sep 17, 2024 · Thimerosal is an ethyl mercury-based preservative used in vials that contain more than one dose of a vaccine (multi-dose vials) to prevent germs, bacteria and/ ...
[32]
Worldwide Ban on Thimerosal Would Cost Lives - Shot of Prevention
Dec 17, 2012 · The use of multi-dose vials reduces the cost of vaccines and the demand on already constrained cold-chain systems (vaccines must be kept at ...
[33]
Global Justice and the Proposed Ban on Thimerosal-Containing ...
Jan 1, 2013 · Thimerosal is an ethyl mercury–containing compound that has been used safely for >60 years as a preservative in multidose vials of vaccines.
[34]
Thimerosal-Containing Vaccines and Neurodevelopmental Disorders
High-doses of thimerosal, ethylmercury, and methylmercury have been found to produce severe health problems. High-dose thimerosal exposures have been iatrogenic ...
[35]
Summary of the Joint Statement on Thimerosal in Vaccines - CDC
In this statement, AAFP, AAP, ACIP, and PHS recommend continuation of the current policy of moving rapidly to vaccines that are free of thimerosal as a ...
[36]
In vitro assessment of Thimerosal cytotoxicity and antimicrobial activity
According to our results Thimerosal should be present in culture media at 100 μg/ml (250 µM) concentration to achieve an effective antimicrobial activity. We ...
[37]
Cosmetics Preservation: A Review on Present Strategies - PMC
In addition, the antimicrobial activity should be sufficiently effective in order to prevent microorganism's adaptation and resistance gain to the preservative ...
[38]
comparison of preservatives efficacy of benzalkonium chloride ...
Aug 7, 2025 · Conclusion: Thimerosal at a minimum concentration of 0.001% exhibited effective concentration as a preservative in eye drops containing 0.5% ...
[39]
Preservative of choice for Prev(e)nar 13™ in a multi-dose formulation
Sep 22, 2011 · These results indicate that 2-PE provides a superior antimicrobial effectiveness over Thimerosal for this vaccine formulation.Missing: efficacy | Show results with:efficacy
[40]
Bacterial resistance to disinfectants: present knowledge and future ...
Different groups of bacteria vary in their susceptibility to biocides, with bacterial spores being the most resistant, followed by mycobacteria, then Gram- ...
[41]
Chemical Disinfectants | Infection Control - CDC
Nov 28, 2023 · ... bacterial spores. Their cidal activity drops sharply when diluted below 50% concentration, and the optimum bactericidal concentration is 60 ...
[42]
Thiomersal - an overview | ScienceDirect Topics
Thimerosal is defined as a mercury-containing preservative used in vaccines to prevent contamination, particularly in open, multidose containers.
[43]
Mercury Levels in Newborns and Infants After Receipt of Thimerosal ...
Feb 1, 2008 · We conducted a pharmacokinetic study to assess blood levels and elimination of ethyl mercury after vaccination of infants with thimerosal-containing vaccines.
[44]
Thiomersal allergy and vaccination reactions - PubMed
Delayed hypersensitivity to thiomersal was demonstrated in 1% of individuals attending the Contact Dermatitis Investigation Unit, and 50 of these patients with ...Missing: acute prevalence
[45]
Sensitization to thimerosal (Merthiolate) is still present today - 1994
Positive patch test reactions to thimerosal (0.1% pet.) were observed in 32 (1.3%) of 2461 adult patients with suspected contact allergy examined in the period ...
[46]
Thiomersal vaccines - World Health Organization (WHO)
A comprehensive review identified 28 publications that addressed mercury blood levels ... half-life of ethyl mercury in blood is between 3 and 7 days. A ...Missing: clearance | Show results with:clearance
[47]
Acrodynia - an overview | ScienceDirect Topics
Acrodynia, or pink disease, occurs in infants and toddlers as a result of chronic exposure to mercury. Painful, persistent erythema and swelling of the hands ...
[48]
Mercury - World Health Organization (WHO)
Oct 24, 2024 · Compared to methylmercury, ethylmercury is very different. Ethylmercury is broken down by the body quickly and does not accumulate. WHO has ...
[49]
Methylmercury and ethylmercury: Different sources, properties and ...
Jul 1, 2004 · Methylmercury and ethylmercury both are organic forms of mercury. Together they differ considerably from the other two species of mercury, elemental and ...
[50]
Minamata Convention on Mercury | US EPA
The wastewater contained methylmercury, which bioaccumulated in fish and shellfish in the bay. Local people who consumed seafood from Minamata Bay became very ...
[51]
The comparative toxicology of ethyl- and methylmercury
Based on both criteria, an equimolar dose of ethylmercury was less neurotoxic than methylmercury, but a 20% increase in the dose of ethylmercury was enough to ...
[52]
Comparative study on methyl- and ethylmercury-induced toxicity in ...
This study was designed to compare the toxicities induced by MeHg and EtHg, as well as by their complexes with cysteine (MeHg-S-Cys and EtHg-S-Cys) in the C6
[53]
Prenatal and Infant Exposure to Thimerosal From Vaccines and ...
OBJECTIVE:. Exposure to thimerosal, a mercury-containing preservative that is used in vaccines and immunoglobulin preparations, has been hypothesized to.
[54]
Vaccine Adverse Event Reporting System 1990–2001 | AJPH - apha
Oct 10, 2011 · Objectives. We investigated vaccine risk perception among reporters of autism to the Vaccine Adverse Event Reporting System (VAERS).Methods.
[55]
Autism: a novel form of mercury poisoning - ScienceDirect.com
Exposure to mercury can cause immune, sensory, neurological, motor, and behavioral dysfunctions similar to traits defining or associated with autism.
[56]
Neurodevelopmental Disorders Following Thimerosal-Containing ...
In the present study, a cohort of children re- ceiving thimerosal-containing diphtheria-tetanus-acellular pertus- sis (DTaP) vaccines in comparison to a cohort ...<|separator|>
[57]
Thimerosal Neurotoxicity is Associated with Glutathione Depletion
Thimerosal-induced cytotoxicity was associated with depletion of intracellular GSH in both cell lines.
[58]
Thimerosal Exposure and the Role of Sulfation Chemistry and Thiol ...
Research indicates that the availability of thiols, particularly GSH, can influence the effects of thimerosal (TM) and other mercury (Hg) compounds. TM is an ...
[59]
[PDF] The Simpsonwood Documents – PDF - Children's Health Defense
convened a special meeting to consider Thimerosal in vaccines. Obviously a ... because it forced us to come to Simpsonwood, probably the only place in ...
[60]
Immunization Safety Review: Vaccines and Autism
Immunization Safety Review: Vaccines and Autism finds that the body of epidemiological evidence favors rejection of a causal relationship between thimerosal- ...
[61]
Autism: a novel form of mercury poisoning - PubMed
Exposure to mercury can cause immune, sensory, neurological, motor, and behavioral dysfunctions similar to traits defining or associated with autism.
[62]
Thimerosal Exposure and the Role of Sulfation Chemistry and Thiol ...
Furthermore, it has recently been demonstrated that polymorphisms in glutathione-related genes modify Hg concentrations and antioxidant status in human subjects ...
[63]
Genetic Aspects of Susceptibility to Mercury Toxicity: An Overview
In this review, the aim is to evaluate a new genetic dimension and its involvement in mercury risk assessment, focusing on the important role played by relevant ...
[64]
Mitochondrial dysfunction, impaired oxidative-reduction activity ...
Thimerosal-induced cellular damage as evidenced by concentration- and time-dependent mitochondrial damage, reduced oxidative-reduction activity, cellular ...
[65]
Persistent behavioral impairments and alterations of brain dopamine ...
Sep 30, 2011 · Early postnatal administration of a vaccine preservative, thimerosal, produces persistent neurobehavioral alteration in rats and changes in brain dopamine ...Missing: dysfunction | Show results with:dysfunction
[66]
Further Evaluation of Altered Neurotoxic Potential in SJL Mice
Neonatal injections of thimerosal in SJL/J mice produced abnormal brain development, delayed growth, and altered locomotor behavior. SJL/J mice have the mouse ...
[67]
Rulemaking History for OTC Topical Antimicrobial Drug Products | FDA
The Status of Over-the-Counter (OTC) Rulemakings contains the citation number of the Federal Register notices organized by therapeutic category subtopics.
[68]
Thimerosal in Vaccines: A Joint Statement of the American Academy ...
Jul 9, 1999 · Thimerosal has been used as an additive to biologics and vaccines since the 1930s because it is very effective in killing bacteria used in several vaccines.
[69]
Impact of the 1999 AAP/USPHS Joint Statement on Thimerosal in ...
On July 8,1999, the American Academy of Pediatrics (AAP) and the US Public Health Service (PHS) jointly recommended reducing infant exposure to thimerosal.
[70]
Timeline of Thimerosal in Vaccines - CDC Archive
The following timeline shows key activities performed by CDC, the U.S. Food and Drug Administration (FDA), the Advisory Committee on Immunization Practices ...
[71]
An Assessment of Thimerosal Use in Childhood Vaccines | Pediatrics
May 1, 2001 · Our review revealed no evidence of harm caused by doses of thimerosal in vaccines, except for local hypersensitivity reactions.
[72]
A Multi-Center Study on Sensitization to Thimerosal in North-Eastern ...
Jun 9, 2025 · A vaccine including 0.01% Thimerosal contains approximately 25 mcg of mercury per dose [6]. More than 20 vaccines authorized in the USA in 2001 ...
[73]
Thiomersal - Substance Information - ECHA - European Union
Here you can find all of the regulations and regulatory lists in which this substance appears, according to the data available to ECHA. This substance has been ...
[74]
[PDF] Thimerosal for Vaccines: AAP Endorses WHO Statement
Dec 17, 2012 · Eliminating thimerosal would effectively eliminate multidose vaccines such as tetanus toxoid, diphtheria-tetanus–whole cell pertussis, and ...
[75]
Multi-dose vials versus single-dose vials for vaccination - NIH
Apr 13, 2022 · Multi-dose vaccine vials translate into greater economic-logistic advantages due to lower packaging and storage costs with significant environmental benefits.<|separator|>
[76]
Thimerosal and the Occurrence of Autism: Negative Ecological ...
Sep 1, 2003 · Conclusions. The discontinuation of thimerosal-containing vaccines in Denmark in 1992 was followed by an increase in the incidence of autism.
[77]
Thimerosal and the occurrence of autism: negative ecological ...
We examined whether discontinuing the use of thimerosal-containing vaccines in Denmark led to a decrease in the incidence of autism. Design: Analysis of data ...Missing: 2002 cohort
[78]
[PDF] thiomersal-and-timerfonate-summary-report-committee-veterinary ...
The mercury content is 45.5%. 2. Thiomersal and timerfonate are organomercuric compounds used as preservatives in vaccines, antigens and immunoglobulins ...Missing: ongoing | Show results with:ongoing
[79]
CDC H1N1 Flu | General Questions and Answers on Thimerosal
Dec 15, 2009 · Thimerosal is an important preservative that protects vaccines against potential microbial contamination, which may occur in opened multi-dose ...
[80]
Vaccine Supply - The 2009 H1N1 Influenza Vaccination Campaign
The greatest challenges in vaccine distribution and administration arose because vaccine supply and demand were poorly matched throughout the 2009 H1N1 ...
[81]
Thimerosal-Containing Vaccines and Autistic Spectrum Disorder
Sep 1, 2004 · Objective. The issue of thimerosal-containing vaccines as a possible cause of autistic spectrum disorders (ASD) and neurodevelopmental ...
[82]
[PDF] Thimerosal as a Vaccine Preservative - CDC
Jun 25, 2025 · The committee “supported prior decisions made by the ACIP and AAP to call for the removal of thimerosal from vaccines that are part of the ...
[83]
CDC vaccine panel recommends avoiding thimerosal in flu vaccines
Jun 26, 2025 · Americans receive only single-dose flu shots that don't include the preservative thimerosal, a theme long pushed by anti-vaccine groups.Missing: endorsement resource settings
[84]
HHS Adopts ACIP Recommendation to Remove Thimerosal From ...
Jul 23, 2025 · The new members of the revamped ACIP, in a vote of 5-1-1, recommended removing the preservative thimerosal from flu shots for the 2025-2026 ...<|separator|>
[85]
Kennedy adopts controversial ACIP recommendation on thimerosal
Jul 23, 2025 · HHS Secretary RFK Jr. accepts recommendations to drop thimerosal from U.S. flu vaccines · Agency says move is intended to 'restore trust,' though ...
[86]
HHS Adopts ACIP Recommendation to Remove Thimerosal from All ...
Jul 23, 2025 · All children 18 years and younger, pregnant women, and adults receive only single-dose influenza vaccines free of mercury.
[87]
4 things to know about the vaccine ingredient thimerosal - NPR
Jul 6, 2025 · Advisers to the Centers for Disease Control and Prevention recommended against flu shots containing the ingredient thimerosal.
[88]
HHS approves flu vaccines without thimerosal, manufacturers ...
Jul 23, 2025 · HHS approves flu vaccines without thimerosal, manufacturers expect no disruptions Available · The U.S. Department of Health and Human Services ( ...
[89]
https://www.aap.org/en/news-room/fact-checked/fact-checked-extensive-research-shows-thimerosal-is-safe/
[90]
Understanding how rare thimerosal-containing flu vaccines are
Jun 26, 2025 · The rate of influenza vaccines without thimerosal was 83% in 2018-2019 and this increased to 96% in the 2024-2025 respiratory virus season.Missing: 2020s | Show results with:2020s
[91]
Maternal and Neonatal Tetanus Elimination
Three doses of Td vaccine are given to all women of child bearing age who live in "high risk areas". This means that 3 rounds of campaign-style activities are ...Missing: thimerosal vials 2020s
[92]
Bacterial contamination of single and multiple-dose parenteral ... - NIH
The overall prevalence of vial contamination due to aerobic bacteria was 21 (5.5%) among multiple-dose vials and none of the single-dose vials. The highest ...
[93]
Single versus multi-dose vaccine vials: An economic computational ...
Jul 19, 2010 · Single-dose vaccine formats can prevent clinic-level vaccine wastage but may incur higher production, medical waste disposal, and storage costs than multi-dose ...
[94]
Thimerosal-Containing Vaccines and Autism: A Review of Recent ...
Certain fish contain methylmercury, and ethylmercury is a component of thimerosal used in vaccines. Although these 2 organic forms of mercury are related, they ...